2-Imidazolidinethione
RTECS #
NI9625000
CAS #
Updated
March 2019
Molecular Weight
102.17
Molecular Formula
C3H6N2S
Synonyms
1,3-Ethylene-2-thiourea
1,3-Ethylenethiourea
2-Imadazoline-2-thiol
2-Mercaptoimidazoline
2-Merkaptoimidazolin (Czech)
2-Thiol-dihydroglyoxaline
4,5-Dihydroimidazole-2(3H)-thione
Akrochem etu-22
Ethylene thiourea
Ethylene thiouree (French)
Ethylenethiourea
ETU
Imidazole-2(3H)-thione, 4,5-dihydro-
Imidazoline, 2-mercapto-
Imidazoline-2-thiol
N,N'-Ethylenethiourea
NA-22
NA-22-D
NCI-C03372
Pennac CRA
RCRA waste number U116
Robac 22
Rodanin S-62 (Czech)
Sanceller 22
Sodium-22 neoprene accelerator
Urea, 1,3-ethylene-2-thio-
USAF EL-62
Vulkacit npv/C2
Warecure C
1,3-Ethylenethiourea
2-Imadazoline-2-thiol
2-Mercaptoimidazoline
2-Merkaptoimidazolin (Czech)
2-Thiol-dihydroglyoxaline
4,5-Dihydroimidazole-2(3H)-thione
Akrochem etu-22
Ethylene thiourea
Ethylene thiouree (French)
Ethylenethiourea
ETU
Imidazole-2(3H)-thione, 4,5-dihydro-
Imidazoline, 2-mercapto-
Imidazoline-2-thiol
N,N'-Ethylenethiourea
NA-22
NA-22-D
NCI-C03372
Pennac CRA
RCRA waste number U116
Robac 22
Rodanin S-62 (Czech)
Sanceller 22
Sodium-22 neoprene accelerator
Urea, 1,3-ethylene-2-thio-
USAF EL-62
Vulkacit npv/C2
Warecure C
Skin and Eye Irritation and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
eye /rabbit | 500 mg/24H | mild | 85JCAE -,988,1986 |
Mutation Data and Reference
System Test | Route/Organism/Tissue | Dose | Reference |
---|---|---|---|
Cytogenetic Analysis | parenteral/rat | 200 mg/kg | MUREAV 38,349,1976 |
Cytogenetic Analysis | oral/rat | 200 mg/kg | CSHCAL 4,267,1977 |
DNA Damage | intraperitoneal/mouse | 2 gm/kg | MUREAV 391,201,1997 |
DNA Damage | /Bacillus subtilis | 2 mg/disc | PMRSDJ 1,175,1981 |
DNA repair | /Escherichia coli | 500 mg/L | PMRSDJ 1,195,1981 |
DNA repair | /Salmonella typhimurium | 20 mg/plate | MUREAV 38,122,1976 |
DNA repair | /Saccharomyes cerevisiae | 300 mg/L | PMRSDJ 1,502,1981 |
gene conversion and mitotic recombination | /Saccharomyes cerevisiae | 50 mg/L | PMRSDJ 1,491,1981 |
gene conversion and mitotic recombination | oral/Drosophila melanogaster | 1 mmol/L/48H | MUREAV 518,95,2002 |
host-mediated assay | Salmonella typhimurium/mouse | 6 gm/kg | MUREAV 56,111,1977 |
morphological transform | kidney/hamster | 80 µg/L | BJCAAI 37,873,1978 |
mutation in microorganisms | lymphocyte/mouse | 1800 mg/L (+enzymatic activation step) | EMMUEG 12,85,1988 |
mutation in microorganisms | /Escherichia coli | 200 mg/L (+enzymatic activation step) | PMRSDJ 1,396,1981 |
mutation in microorganisms | /Salmonella typhimurium | 1 mmol/L (+enzymatic activation step) | EXPEAM 31,214,1975 |
mutation in microorganisms | /Salmonella typhimurium | 20 µg/plate (-enzymatic activation step) | BJCAAI 37,873,1978 |
mutation in microorganisms | /Saccharomyes cerevisiae | 5 mmol/L (-enzymatic activation step) | MGGEAE 174,39,1979 |
phage inhibition capacity | /Escherichia coli | 10 gm/L | PMRSDJ 1,224,1981 |
sex chromosome loss and nondisjunction | /Saccharomyes cerevisiae | 100 mg/L | PMRSDJ 1,468,1981 |
sex chromosome loss and nondisjunction | /Aspergillus nidulans | 39200 µmol/L | MUREAV 172,139,1986 |
specific locus test | multiple/Drosophila melanogaster | 500 µmol/L | MUREAV 395,229,1997 |
Reproductive Effects Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
inhalation/rat | 120 mg/m3/3H (7-14D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on embryo or fetus: Fetal death | NTIS** PB277-077 |
inhalation/rat | 27200 µg/m3/3H (7-14D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | NTIS** PB277-077 |
intraperitoneal/rat | 30 mg/kg (17D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Effects on newborn: Weaning or lactation index (e.g., # alive at weaning per # alive at day 4) | TJADAB 34,449,1986 |
intraperitoneal/rat | 30 mg/kg (19D pregnant) | Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) | TJADAB 34,449,1986 |
intraperitoneal/rat | 30 mg/kg (12D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) | CGANE7 30,121,1990 |
intraperitoneal/rat | 30 mg/kg (13D pregnant) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | CGANE7 30,121,1990 |
oral/rat | 84 mg/kg (11-14D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | JHSCFD 45,184,1999 |
oral/rat | 60 mg/kg (13D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | TJADAB 24,131,1981 |
oral/rat | 100 mg/kg (13D pregnant) | Reproductive: Specific developmental abnormalities: Gastrointestinal system | SEIJBO 18,241,1978 |
oral/rat | 60 mg/kg (13D pregnant) | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | FCTOD7 20,273,1982 |
oral/rat | 10 mg/kg (17D pregnant) | Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) Reproductive: Effects on newborn: Weaning or lactation index (e.g., # alive at weaning per # alive at day 4) | ATSUDG 4,292,1980 |
oral/rat | 50 mg/kg (12D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | SEIJBO 18,241,1978 |
oral/rat | 30 mg/kg (15D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Effects on newborn: Weaning or lactation index (e.g., # alive at weaning per # alive at day 4) | FAATDF 9,415,1987 |
oral/mouse | 1600 mg/kg (12D pregnant) | Reproductive: Effects on newborn: Sex ratio | JTEHD6 13,747,1984 |
oral/mouse | 2 gm/kg (7-16D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | JTEHD6 5,821,1979 |
oral/mouse | 2 gm/kg (10D pregnant) | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | TJADAB 23,335,1981 |
oral/mouse | 2 gm/kg (12D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Specific developmental abnormalities: Musculoskeletal system | TJADAB 27,57A,1983 |
oral/mouse | 2400 mg/kg (12D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | TJADAB 27,57A,1983 |
oral/cat | 600 mg/kg (16-35D pregnant) | Reproductive: Specific developmental abnormalities: Eye, ear Reproductive: Specific developmental abnormalities: Body wall Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | TJADAB 18,311,1978 |
oral/rabbit | 1120 mg/kg (7-20D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | TJADAB 7,243,1973 |
oral/rabbit | 140 mg/kg (7-20D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system | TJADAB 7,243,1973 |
oral/hamster | 600 mg/kg (11D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | JTEHD6 11,287,1983 |
oral/hamster | 6480 mg/kg (6-18D pregnant) | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Gastrointestinal system | SEIJBO 18,11,1978 |
oral/hamster | 2400 mg/kg (11D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death | JTEHD6 11,287,1983 |
oral/hamster | 2160 mg/kg (6-13D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | SEIJBO 18,11,1978 |
oral/hamster | 1200 mg/kg (11D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | JTEHD6 11,287,1983 |
oral/rat | 3.6 mg/kg (7-20D preg/22D after birth) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Specific developmental abnormalities: Endocrine system | FCTOD7 59,261,2013 |
skin/rat | 100 mg/kg (12-13D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Specific developmental abnormalities: Musculoskeletal system | TXAPA9 41,35,1977 |
skin/rat | 2800 mg/kg (7D prior to copulation/1-21D pregnant) | Reproductive: Maternal effects: Parturition Reproductive: Effects on newborn: Stillbirth Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | TOXID9 12,102,1992 |
subcutaneous/rat | 80 mg/kg (13D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | TXAPA9 48,229,1979 |
subcutaneous/rat | 80 mg/kg (13D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Homeostasis | TXAPA9 48,229,1979 |
unreported route/rat | 300 mg/kg (12D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Specific developmental abnormalities: Musculoskeletal system | AHEMA5 9,89,1980 |
Tumorigenic Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
oral/mouse | lowest published toxic dose: 87360 mg/kg/2Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors Endocrine: Thyroid tumors | NTPTR* NTP-TR-388,1992 |
oral/mouse | lowest published toxic dose: 77 gm/kg/82W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors Blood: Lymphoma including Hodgkin's disease | JNCIAM 42,1101,1969 |
oral/mouse | lowest published toxic dose: 86520 mg/kg/103W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors Endocrine: Thyroid tumors | NTIS** PB92-191618 |
oral/rat | lowest published toxic dose: 10920 mg/kg/2Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | NTPTR* NTP-TR-388,1992 |
oral/rat | lowest published toxic dose: 5306 mg/kg/77W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Lung, Thorax, or Respiration: Tumors Endocrine: Thyroid tumors | JNCIAM 49,583,1972 |
oral/rat | toxic dose: 11466 mg/kg/78W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | JJIND8 67,75,1981 |
oral/rat | toxic dose: 44 gm/kg/2Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors Reproductive: Tumorigenic effects: Testicular tumors | EJTXAZ 9,303,1976 |
oral/rat | toxic dose: 146 gm/kg/2Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | EJTXAZ 9,303,1976 |
oral/rat | toxic dose: 9125 mg/kg/2Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Tumors Endocrine: Thyroid tumors | FCTXAV 13,493,1975 |
oral/rat | toxic dose: 5470 mg/kg/26W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Liver: Tumors | GTPZAB 32(2),25,1988 |
oral/rat | lowest published toxic dose: 2737.5 mg/kg/1Y- continuous | Tumorigenic: Neoplastic by RTECS criteria Endocrine: Thyroid tumors | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 5475 mg/kg/1Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 9125 mg/kg/1Y- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 10815 mg/kg/103W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | NTIS** PB92-191618 |
oral/rat | lowest published toxic dose: 9012.5 mg/kg/103W- continuous | Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Thyroid tumors | NTIS** PB92-191618 |
Acute Toxicity Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
In Vitro/Human, kidney | Inhibitor Concentration (20 percent kill): >100 µmol/L/2H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 40,66,2017 |
In Vitro/Human, kidney | Inhibitor Concentration (20 percent kill): >100 µmol/L/2H | Endocrine: Other changes | TIVIEQ 40,66,2017 |
intraperitoneal/mouse | lethal dose (50 percent kill): 200 mg/kg | NTIS** AD277-689 | |
intraperitoneal/rat | lowest published toxic dose: 1000 mg/kg | Endocrine: Other changes | ATSUDG 8,253,1985 |
oral/mouse | lethal dose (50 percent kill): 3 gm/kg | TJADAB 21,71,1980 | |
oral/rat | lethal dose (50 percent kill): 1832 mg/kg | BECTA6 7,19,1972 | |
Tank with water/Daphnia | lethal concentration (50 percent kill): 18000 µg/L/21D | AQUTO* 7,165,1985 | |
Tank with water/Zebrafish | the toxic concentration that affects 50% of the population of interest): 139.9 µmol/L/3D | Endocrine: Evidence of thyroid hypofunction | TXAPA9 269,169,2013 |
Tank with water/Zebrafish | the toxic concentration that affects 10% of the population of interest): 22.6 µmol/L/3D | Endocrine: Evidence of thyroid hypofunction | TXAPA9 269,169,2013 |
unreported route/mouse | lethal dose (50 percent kill): 7800 mg/kg | GTPZAB 30(5),59,1986 |
Other Multiple Dose Data and References
Route/Organism | Dose | Effect | Reference |
---|---|---|---|
inhalation/man | lowest published toxic concentration: 10 µg/m3/10Y- intermittent | Endocrine: Evidence of thyroid hypofunction | BJIMAG 41,362,1984 |
oral/mouse | lowest published toxic dose: 277.2 mg/kg/7D- continuous | Liver: Changes in liver weight Endocrine: Evidence of thyroid hypofunction | EVHPAZ 110,363,2002 |
oral/mouse | lowest published toxic dose: 840 mg/kg/7D- continuous | Liver: Changes in liver weight Endocrine: Evidence of thyroid hypofunction Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Cytochrome oxidases (indlucing oxidative phosphrylation) | EVHPAZ 110,363,2002 |
oral/rat | lowest published toxic dose: 39.375 mg/kg/7D- intermittent | Endocrine: Other changes | MUREAV 746,144,2012 |
oral/rat | lowest published toxic dose: 504 mg/kg/28D- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Biochemical: Metabolism (intermediary): Other | TOLED5 225,240,2014 |
oral/rat | lowest published toxic dose: 504 mg/kg/28D- continuous | Biochemical: Metabolism (intermediary): Other | TOLED5 225,240,2014 |
oral/rat | lowest published toxic dose: 34.86 mg/kg/7D- continuous | Endocrine: Evidence of thyroid hypofunction Endocrine: Changes in thyroid weight | EVHPAZ 110,363,2002 |
oral/rat | lowest published toxic dose: 29.05 mg/kg/7D- continuous | Endocrine: Evidence of thyroid hypofunction | EVHPAZ 110,363,2002 |
oral/rat | lowest published toxic dose: 297 mg/kg/28D- continuous | Endocrine: Other changes Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | ATSUDG 9,339,1986 |
oral/rat | lowest published toxic dose: 764 mg/kg/90D- continuous | Endocrine: Other changes Endocrine: Changes in thyroid weight Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | JEPTDQ 1(1),147,1977 |
oral/rat | lowest published toxic dose: 220 mg/kg/7W- continuous | Behavioral: Food intake (animal) Endocrine: Changes in thyroid weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TXAPA9 67,264,1983 |
oral/rat | lowest published toxic dose: 3600 mg/kg/17W- continuous | Endocrine: Other changes Endocrine: Changes in thyroid weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | BECTA6 7,19,1972 |
oral/rat | lowest published toxic dose: 450 mg/kg/8W- continuous | Liver: Changes in liver weight | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 900 mg/kg/8W- continuous | Endocrine: Changes in thyroid weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 1800 mg/kg/8W- continuous | Kidney, Ureter, and Bladder: Changes in kidney weight | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 5475 mg/kg/26W- continuous | Endocrine: Changes in spleen weight | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 10950 mg/kg/1Y- continuous | Endocrine: Evidence of thyroid hypofunction | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 75 mg/kg/8W- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 375 mg/kg/8W- continuous | Liver: Changes in liver weight Endocrine: Changes in thyroid weight | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 1140.6 mg/kg/26W- continuous | Endocrine: Evidence of thyroid hypofunction | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 2281 mg/kg/1Y- continuous | Endocrine: Evidence of thyroid hyperfunction | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 2281 mg/kg/26W- continuous | Cardiac: Changes in heart weight | JAFCAU 21,324,1973 |
oral/rat | lowest published toxic dose: 1500 mg/kg/8W- continuous | Kidney, Ureter, and Bladder: Changes in kidney weight Endocrine: Changes in spleen weight | JAFCAU 21,324,1973 |
Reviews
Organization | Standard | Reference |
---|---|---|
International Agency for Research on Cancer (IARC) | Cancer Review:Animal Sufficient Evidence | IMEMDT 79,-,2000 |
International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 79,-,2000 |
International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMEMDT 79,-,2000 |
TOXICOLOGY REVIEW | ENVRAL 7,243,1974 | |
TOXICOLOGY REVIEW | AIHAAP 39(6),A34,1978 | |
TOXICOLOGY REVIEW | 85CVA2 5,250,1970 | |
TOXICOLOGY REVIEW | CNDQA8 14,49,1979 | |
TOXICOLOGY REVIEW | MUREAV 567,227,2004 | |
TOXICOLOGY REVIEW | MUREAV 627,59,2007 | |
TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
TOXICOLOGY REVIEW | MUREAV 654,114,2008 | |
TOXICOLOGY REVIEW | JTPAE7 17,69,2004 | |
TOXICOLOGY REVIEW | REPTED 26,1,2008 | |
TOXICOLOGY REVIEW | HTOPA* 1,501,2002 | |
TOXICOLOGY REVIEW | IMEMDT 79,659, | |
TOXICOLOGY REVIEW | MUREAV 741,32,2012 | |
TOXICOLOGY REVIEW | MUREAV 760,1,2014 | |
TOXICOLOGY REVIEW | FCTOD7 55,596,2013 | |
TOXICOLOGY REVIEW | MUREAV 802,1,2016 | |
TOXICOLOGY REVIEW | NETEEC 52,25,2015 | |
TOXICOLOGY REVIEW | TOLED5 254,52,2016 | |
TOXICOLOGY REVIEW | RTOPDW 55,43,2009 | |
TOXICOLOGY REVIEW | RTOPDW 61,251,2011 | |
TOXICOLOGY REVIEW | RTOPDW 60,S1,2011 |
Standards and Regulations
NIOSH Documentation and Surveillance
Organization | Standard | Reference |
---|---|---|
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO ETHYLENE THIOUREA-air | Carcinogen lowest feasible concentration | NIOSH* DHHS #92-100,1992 |
National Occupational Exposure Survey 1983 | Hazard Code 82079; Number of Industries 11; Total Number of Facilities 462; Number of Occupations 24; Total Number of Employees Exposed 10749; Total Number of Female Employees Exposed 1804 | |
National Occupational Hazard Survey 1974 | Hazard Code 82079; Number of Industries 13; Total Number of Facilities 1100; Number of Occupations 39; Total Number of Employees Exposed 7475 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health